Icon

EXFORGE (nda021990)- (EQ 5MG BASE;160MG,EQ 10MG BASE;160MG,EQ 5MG BASE;320MG,EQ 10MG BASE;320MG)

AMLODIPINE BESYLATE; VALSARTAN NOVARTIS
EQ 5MG BASE;160MG,EQ 10MG BASE;160MG,EQ 5MG BASE;320MG,EQ 10MG BASE;320MG
Yes Yes
2019-Jul-08 Expired
None None
None No
Exforge is the combination tablet of amlodipine, a dihydropyridine calcium channel blocker (DHP CCB), and valsartan, an angiotensin II receptor blocker (ARB). Exforge is indicated for the treatment of hypertension, to lower blood pressure: • In patients not adequately controlled on monotherapy • As initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals.
8 0 6
Total Other Developers 11
Drugs with Suitability No
EQ 5MG BASE;160MG ** ** - - 4
EQ 10MG BASE;160MG ** ** - - 4
EQ 5MG BASE;320MG ** ** - - 4
EQ 10MG BASE;320MG ** ** - - 4
NDA Sales Available Total Generic Sales Available
Yes 6
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ***** ***** ******* *********** **** **. **-*, ***** *-*, ***** ********** ****, *****, ********, *** ******, ***** (***) ***
****** ******* ******* *************** ******* *********** *********** ********, ******* *******, *.*. *******, **** *****, ****** *****,, **********, ******* ******, ***** (***) ***
****** ***** **** *** ***** ************, ***. *********** *** ****** *****, ********, *** ****** (**) *****, ****** ****** (***) ***
****** ********* ****** ********* ****** ******* *********** ****-***, ** **. ***/*, ***/*, ***/*, ***/* & ***/*, **** ** **** ***, *****, ***** ********** ****, *********, ********* ******, ************, ********* ******, ***** (***) ***
****** ******* ****** ******* ******, *** *********** * *** ***** **, ******** *****, *** **** (**) *****-****, ****** ****** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.